Human sera from 20 participants who received both doses of the Pfizer\/BioNTech vaccine showed equivalent neutralization titers (with differences of four-fold or less) between wild type and variants strains of SARS-CoV-2 viruses that were engineered to contain spike proteins from recently emerged variants. The combinations of mutations included N501Y (present in variants emerging from the UK and South Africa), 69\/70-deletion + N501Y\u2009+\u2009D614G (first described in the UK), and E484K\u2009+\u2009N501Y\u2009+\u2009D614G (first described in South Africa). Neutralization geometric mean titers (GMTs) against the three variant strains were 0.8- to 1.5-fold that of the GMTs against parental virus, suggesting small impacts of these mutations on neutralization by sera from vaccinated individuals. The authors note a limitation that the engineered viruses do not contain the full set of mutations\u00a0present in the variants. [EDITORIAL NOTE: This manuscript was summarized previously as a pre-print on January 28.]<\/i><\/p>\n
Xie et al. (Feb 8, 2021). Neutralization of SARS-CoV-2 Spike 69\/70 Deletion, E484K and N501Y Variants by BNT162b2 Vaccine-Elicited Sera. Nature Medicine. <\/i>https:\/\/doi.org\/10.1038\/s41591-021-01270-4<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Human sera from 20 participants who received both doses of the Pfizer\/BioNTech vaccine showed equivalent neutralization titers (with differences of four-fold or less) between wild type and variants strains of SARS-CoV-2 viruses that were engineered to contain spike proteins from recently emerged variants. The combinations of mutations included N501Y (present in variants emerging from the…<\/p>\n